Boehringer Ingelheim’s investigational asset apecotrep delivers proteinuria reduction in Phase II kidney trial
Not intended for the UK Apecotrep (BI 764198) is a potential first-in-class, oral, selective TRPC6 inhibitor being investigated as a novel, targeted, non-immunosuppressive therapy in people with primary focal segmental glomerulosclerosis (FSGS). Primary FSGS is a rare kidney condition in which injury and loss of podocytes, the cells responsible for the kidney’s filtration system, lead [...]










